BURDEN OF BRAIN METASTASES (BM) IN ALK plus NON-SMALL CELL LUNG CANCER (ALK plus NSCLC) TREATED WITH FIRST-LINE ALK INHIBITORS: RESULTS OF A SYSTEMATIC LITERATURE REVIEW (SLR)

被引：0
|
作者：
Pan, X. [1 ]
Kwon, C. S. [2 ]
Garib, S. A. [2 ]
Forsythe, A. [2 ]
Lin, H. M. [1 ]
机构：
[1] Millennium Pharmaceut Inc, Cambridge, MA USA
[2] Purple Squirrel Econ, New York, NY USA
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN22
引用
收藏
页码：S439 / S439
页数：1
相关论文
共 50 条
  • [11] Symptoms of Bone and Liver Metastases in Patients with ALK plus Non-Small Cell Lung Cancer (NSCLC)
    Guerin, Annie
    Sasane, Medha
    Nitulescu, Roy
    Zhang, Jie
    Culver, Kenneth W.
    Wu, Eric Q.
    Macalalad, Alexander R.
    Dalai, Anand
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S412 - S412
  • [12] Optimal first-line treatment for metastatic ALK plus non-small cell lung cancer-a narrative review
    Chazan, Grace
    Solomon, Benjamin J.
    TRANSLATIONAL LUNG CANCER RESEARCH, 2023, 12 (02) : 369 - 378
  • [13] AN ECONOMIC SYSTEMATIC LITERATURE REVIEW (SLR) FOR ANAPLASTIC LYMPHOMA KINASE-POSITIVE (ALK plus ) NON-SMALL-CELL LUNG CANCER (NSCLC)
    Robson, R. E.
    Cranmer, H.
    Huang, J.
    Selby, R.
    Lin, H. M.
    Tolley, K.
    VALUE IN HEALTH, 2018, 21 : S47 - S47
  • [14] DURATION OF TREATMENT AND ECONOMIC BURDEN IN PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE POSITIVE (ALK plus ) NON-SMALL CELL LUNG CANCER (NSCLC) RECEIVING SECOND-LINE ALK INHIBITORS
    Lin, H. M.
    Hou, P.
    Huang, H.
    Desai, A.
    Jahanzeb, M.
    VALUE IN HEALTH, 2018, 21 : S17 - S17
  • [15] CERITINIB (LDK378) FOR TREATMENT OF PATIENTS WITH ALK-REARRANGED (ALK plus ) NON-SMALL CELL LUNG CANCER (NSCLC) AND BRAIN METASTASES (BM) IN THE ASCEND-1 TRIAL
    Shaw, Alice
    Mehra, Ranee
    Tan, Daniel S. W.
    Felip, Enriqueta
    Chow, Laura Q. M.
    Camidge, D. Ross
    Vansteenkiste, Johan
    Sharma, Sunil
    De Pas, Tommaso
    Riely, Gregory J.
    Solomon, Benjamin J.
    Wolf, Juergen
    Thomas, Michael
    Schuler, Martin
    Liu, Geoffrey
    Santoro, Armando
    Geraldes, Margarida
    Sen, Paramita
    Boral, Anthony J.
    Yovine, Alejandro
    Kim, Dong-Wan
    NEURO-ONCOLOGY, 2014, 16
  • [16] ALK inhibitors in ALK-rearranged non-small cell lung cancer with and without brain metastases: systematic review and network meta-analysis
    Jiang, Jun
    Zhao, Cong
    Zhang, Fang
    Liu, Zhenhua
    Zhou, Kaiyuan
    Ren, Xinling
    Wan, Yi
    BMJ OPEN, 2022, 12 (09):
  • [17] Clinical experience with crizotinib in patients (pts) with advanced ALK plus non-small cell lung cancer (NSCLC) and brain metastases
    Crino, L.
    Ahn, M. J.
    Ou, S. H. I.
    Solomon, B. J.
    Costa, D. B.
    Shreeve, S. M.
    Wiltshire, R.
    Selaru, P.
    Zhou, C.
    Riely, G. J.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S800 - S800
  • [18] Sequencing of ALK Inhibitors in ALK+ Non-Small Cell Lung Cancer
    Shirish M. Gadgeel
    Current Treatment Options in Oncology, 2017, 18
  • [19] Brain metastases in patients with ALK plus non-small cell lung cancer: clinical symptoms, treatment patterns and economic burden
    Guerin, Annie
    Sasane, Medha
    Zhang, Jie
    Culver, Kenneth W.
    Dea, Katherine
    Nitulescu, Roy
    Wu, Eric Qiong
    JOURNAL OF MEDICAL ECONOMICS, 2015, 18 (04) : 312 - 322
  • [20] LORLATINIB AS A FIRST-LINE TREATMENT FOR ALK plus ADVANCED NON-SMALL CELL LUNG CANCER: A COSTEFFECTIVENESS ANALYSIS IN SPAIN
    Presa, M.
    Vicente, D.
    Calles, A.
    Salinas-Ortega, L.
    Naik, J.
    Garcia, L. F.
    Soto, J.
    VALUE IN HEALTH, 2022, 25 (12) : S90 - S91
12345